Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | PON1 | P27169 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21116465 | 0.84 | TP53 (0.46) | TP53MAPTSMN1; SMN2EPHX2MTNR1B | |
| SCHEMBL18015849 | 0.81 | MTNR1A (0.45) | TP53MAPTSMN1; SMN2MTNR1B | |
| SCHEMBL21116466 | 0.81 | TP53 (0.46) | TP53MAPTSMN1; SMN2EPHX2MTNR1B | |
| SCHEMBL17107455 | 0.81 | MAOB (0.44) | TP53MAPTSMN1; SMN2EPHX2MTNR1B | |
| SCHEMBL16619764 | 0.81 | TP53 (0.43) | TP53MAPTSMN1; SMN2EPHX2MTNR1B | |
| SCHEMBL18014738 | 0.78 | PON1 (0.58) | MAPTPON1MAOA | |
| SCHEMBL4446704 | 0.75 | KIF11 (0.42) | TP53MAPTSMN1; SMN2EPHX2KIF11 | |
| SCHEMBL17324189 | 0.75 | MTNR1A (0.40) | TP53MAPTSMN1; SMN2MTNR1BKIF11 | |
| SCHEMBL12776232 | 0.73 | CA2 (0.50) | MAOAMAOB | |
| SCHEMBL25037452 | 0.72 | PON1 (0.51) | TP53MAPTSMN1; SMN2MTNR1BPON1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | TP53 2499/4885MAPT 358/4885SMN1; SMN2 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.